Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 67
- Registration Number
- NCT00513305
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Indiana Oncology Hematology Consultants, Indianapolis, Indiana, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
- Conditions
- Acute Promyelocytic Leukemia
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT00504764
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital de Mataró, Mataró, Barcelona, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- University of Miami
- Registration Number
- NCT00504101
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Phase III Trial in Acute Promyelocytic Leukemia Patients
- Conditions
- Leukemia
- Interventions
- Drug: all-trans retinoic acid (ATRA)
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2022-10-12
- Target Recruit Count
- 276
- Registration Number
- NCT00482833
- Locations
- 🇦🇹
Universitätsklinik Innsbruck Hämatologie Onkologie, Innsbruck, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria
🇦🇹Universitätsklinik für Innere Medizin III Salzburg, Salzburg, Austria
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
- Conditions
- Myeloma
- Interventions
- Drug: Vitamin C (Ascorbic Acid)
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00469209
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 2000
- Registration Number
- NCT00454480
- Locations
- 🇬🇧
Queen's Hospital, Burton-upon-Trent, England, United Kingdom
🇬🇧Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
🇬🇧Hereford Hospitals, Hereford, United Kingdom
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
- Conditions
- Colorectal Cancer
- Interventions
- Other: Plasma levels of elemental arsenicGenetic: Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysisProcedure: Tumor Biopsy (Fine-Needle Aspiration)
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 13
- Registration Number
- NCT00449137
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- Drug: All-Trans Retinoic Acid (ATRA)
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT00413166
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Leukemia
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00274781
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.